C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib

BACKGROUND AND AIM: Lenvatinib has become a first line treatment for unresectable hepatocellular carcinoma (HCC). However, continued administration is impossible in many patients due to treatment resistance and severe adverse events. This study aimed to identify predicting factors to select patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Tsuguru, Shibata, Michihiko, Oe, Shinji, Miyagawa, Koichiro, Honma, Yuichi, Harada, Masaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755182/
https://www.ncbi.nlm.nih.gov/pubmed/33351844
http://dx.doi.org/10.1371/journal.pone.0244370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755182/
https://www.ncbi.nlm.nih.gov/pubmed/33351844
http://dx.doi.org/10.1371/journal.pone.0244370

Ejemplares similares